# **Pretomanid and the BPaL Regimen** NOW INCLUDED IN THE WORLD HEALTH ORGANIZATION GUIDELINES FOR THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS

Pretomanid was developed by TB Alliance as an oral tablet formulation for the treatment of tuberculosis (TB) in combination with other anti-TB agents.

In August 2019, pretomanid received its first regulatory approval from the U.S. Food and Drug Administration (FDA) as part of a treatment regimen in combination with bedaquiline and linezolid, commonly called BPaL (bee-pal). The regimen was approved for the treatment of people with highly drug-resistant TB (DR-TB).



HEAR THE #TBCOURAGE STORIES OF THOSE TREATED WITH BPAL

89%

with

92%

TI/NR<sup>†</sup> MDR-TB

79-95 (95% CI)

79-98 (95% CI)







DATA FROM TB ALLIANCE CLINICAL TRIALS HAVE SUPPORTED THE APPROVAL AND EXTENDED US OF BPAL ZeNix: An Open-Label, Four-Group Study

> 95% CI (83-95) Clinical resolution 6 months after therapy

were **HIV+** 

91%

participants that were **HIV-**92%

The results were consistent regardless of HIV status.



MARIIA, cured with BPaL in Kyiv

PANGANAI, cured with BPaL in Johannesburg





With critical support from funders, partners, and other stakeholders, TB Alliance developed pretomanid from a preclinical compound through a regulatory approval.

**READ THE WHO GUIDELINES** 



## THE FUTURE OF TB TREATMENT

Prior to the introduction of BPaL, treatment of highly DR-TB was lengthy and complex. Most extensively drug-resistant TB (XDR-TB) patients took a combination of up to eight antibiotics for 18 months or longer, with little chance of curing their TB.

Old								
MONTH 1	MONTH 2	MONTH 3	MONTH 4	MONTH 5	MONTH 6			
MONTH 7	MONTH 8	MONTH 9	MONTH 10	MONTH 11	MONTH 12			
MONTH 13	MONTH 14	MONTH 15	MONTH 16	MONTH 17	MONTH 18			
MONTH 19	MONTH 20							

**THE RESULTS** 

93.4% of all participants completed the full course of treatment

**89%** of all participants had favorable outcomes

Bacteriological and **Clinical Resolution** 6 months after therapy

**Favorable outcomes** Group 1

\*• \*• \*• \*• \*•

Group 2 ••••

Group 3 • • • • •

Group 4





**ANNA CHRISTINA, cured with BPaL in Manilla** 







SCAN ME





	V			
		Line	e <b>zolid</b> per day	
			200mg 00mg	
5		=	1 month	
	93%			
		81.3-98.6	6 (95% CI)	
	89%			
		75.9-96.3	8 (95% CI)	
	91%			
		78.3-97.5	5 (95% CI)	

69.9-93.4 (95% CI)

**BESIK, cured with BPaL in Tbilisi**